The New Benchmark


The technologic edge that Tispa provides is to reduce the risk of misdiagnosis from defective tissue processing to near zero. In an analysis of the diagnoses of breast tissue biopsies from 155 different pathologists and 240 samples, it was found that the risk of misdiagnosing biopsies is very real. Our aim, among other things, has been to help medical professionals mitigate that risk while providing them with a level of tissue quality enabling molecular diagnostics. We achieve this thanks to our patented process, that uses lower processing temperatures and softer reagents. Lower process temperature causes less tissue degradation with superior DNA/RNA yield, while providing higher contrast in the staining of samples. A sharper image and stronger coloration of cells allows for a more accurate diagnosis and zero error. Our entire process operates to ISO 15189 standards for complex oncological tissue as set by the Joint Commission International (“JCI”).

All The Benefits


For the Pathologist

  • Clean ethanol every run so no cross contamination.
  • Using CO2 instead of xylene leads to in bright staining of the tissues.
  • More efficient workload due to an even flow of tissues during the day.
  • High quality and yield of DNA/RNA results in superior molecular diagnostics.

For The Manager

  • Clean working environment, no exposure to toxic clearing agents and no decanting of ethanol required.
  • Tispa reduces running costs with 50% compared to traditional tissue processors.
  • Efficient workflow by processing all types of tissue in 3 hours or less with two independent working retorts.
  • No destruction of tissues in case of a run error.
  • A Return of Investment of 1 year.

For the Staff

  • Standard grossing rules, there is no need to change any grossing procedure.
  • Easy slicing of impregnated tissues.
  • No pre- of after treatment for gross cut fatty tissues.
  • Easy handling of reagents and waste.

For The Patient

  • Reduced period of anxiety and uncertainty.
  • Necessary treatment can commence faster.
  • Zero chance of re-biopsy.

Superior Diagnostics

Tissue1 WS
Tissue2 WS
Tissue3 WS
Tissue4 WS

Competitor Analysis

There have been important developments in the industry over the years, some being: same day diagnosis for mixed tissue types, molecular diagnosis, solvent free applications, and improved workflows. However, modern solutions available in the marketplace today do not combined all these developments into one machine. Tispa 2 is the first of a new generation of machine enabling all these capabilities to be found in a single tissue processor. It offers clean, fast, versatile, and failure proof high quality tissue processing, setting the standard for the future of molecular diagnostics. As an affordable investment with significantly lower operating costs, delivering optimal quality, the benefits to all stakeholders are self-evident. Within a year of purchase, our machine will deliver a full return on investment, increase patient safety, while decreasing false positives and negatives.
Graph - Comparison

Table 1

shows how Tispa scores addressing the major trends compared to other processing technologies.
Graph - Operational Costs

Table 2

shows the operational costs per cassette of Tispa compared to other processing technologies.
Graph - Capital Costs

Table 3

shows the Capital Costs per cassette based on single year depreciation using the maximum throughput of Tispa compared to other processing technologies.

This website uses cookies to ensure you get the best experience on our website. Learn more